Literature DB >> 27003681

Prolonged Duration of Renal Recovery Following ANCA-Associated Glomerulonephritis.

Amin Oomatia1, Sarah M Moran, Claire Kennedy, Rachel Sequeira, Sally Hamour, Aine Burns, Mark A Little, Alan D Salama.   

Abstract

BACKGROUND: As renal biopsies are not routinely repeated to monitor treatment response in anti-neutrophil cytoplasm antibody (ANCA)-associated glomerulonephritis, serum creatinine (SC) and proteinuria assessed by urine protein:creatinine ratio (UPCR) measurements are relied upon to provide a non-invasive estimate of disease activity within the kidney. However, sparse information exists about the time to achieve maximal improvement in these parameters, which has important implications for treatment decisions and disease-scoring systems.
METHODS: We analysed patients with ANCA-associated glomerulonephritis and renal impairment from cohorts in the United Kingdom and Ireland, with the primary objective of determining actuarial time to nadir SC and UPCR. Time to disappearance of haematuria was analysed as a secondary objective.
RESULTS: Ninety-four patients fulfilled our selection criteria, with 94 (100%) and 66 (70%) having reached their nadir SC and UPCR respectively during the follow-up period. Nadir SC was achieved after a median of 88 days (95% CI 74-102), UPCR at 346 days (95% CI 205-487). Those of Indo-Asian ethnic origin reached their nadir SC faster (34 days) than other ethnicities (p < 0.01). There were no significant differences in time to nadir SC or UPCR on the basis of gender, clinical diagnosis, ANCA positivity or renal biopsy findings.
CONCLUSION: In this retrospective study, nadir creatinine and proteinuria occur later than other signs of clinical remission, suggesting that ongoing renal recovery continues for a significant time after diagnosis. It may benefit disease-scoring systems to take into account SC levels beyond the initial assessment.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27003681     DOI: 10.1159/000444925

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  3 in total

Review 1.  Update on ANCA-associated vasculitis: from biomarkers to therapy.

Authors:  Martina Tedesco; Maurizio Gallieni; Francesca Pellegata; Mario Cozzolino; Federico Alberici
Journal:  J Nephrol       Date:  2019-07-12       Impact factor: 3.902

2.  Current and novel biomarkers in anti-neutrophil cytoplasm-associated vasculitis.

Authors:  Juliana Bordignon Draibe; Xavier Fulladosa; Josep Maria Cruzado; Joan Torras; Alan David Salama
Journal:  Clin Kidney J       Date:  2016-06-29

3.  Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Sarah M Moran; Paul A Monach; Lina Zgaga; David Cuthbertson; Simon Carette; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Larry Moreland; Christian Pagnoux; Philip Seo; Ulrich Specks; Antoine Sreih; Jason Wyse; Steven R Ytterberg; Peter A Merkel; Mark A Little
Journal:  Nephrol Dial Transplant       Date:  2020-02-01       Impact factor: 7.186

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.